Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis (Q35627661)

9 August 2017

1 reference

title

Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis (English)

1 reference

9 August 2017

0 references

multiple drug resistance

1 reference

Conway SP

1

1 reference

9 August 2017

Brownlee KG

series ordinal

2

1 reference

9 August 2017

Denton M

series ordinal

3

1 reference

9 August 2017

Peckham DG

series ordinal

4

1 reference

9 August 2017

1 January 2003

1 reference

Treatments in Respiratory Medicine

9 August 2017

1 reference

9 August 2017

2

1 reference

9 August 2017

321-332

1 reference

9 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1007/bf03256660

9 August 2017

0 references

cites work

Lower airway inflammation in infants and young children with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disc susceptibility test

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Inhibition of Pseudomonas aeruginosa exoenzyme expression by subinhibitory antibiotic concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Ability of azlocillin and tobramycin in combination to delay or prevent resistance development in Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Once-daily tobramycin in the treatment of adult patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Four years' experience of intravenous colomycin in an adult cystic fibrosis unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Molecular epidemiology of Pseudomonas aeruginosa infections in a cystic fibrosis outpatient clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Pseudomonas aeruginosa in cystic fibrosis: cross-infection and the need for segregation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Superinfection with a transmissible strain of Pseudomonas aeruginosa in adults with cystic fibrosis chronically colonised by P aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Burkholderia cepacia complex infection in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Taxonomy and identification of the Burkholderia cepacia complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Endemicity and inter-city spread of Burkholderia cepacia genomovar III in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Outcome for patients colonised with Burkholderia cepacia in a Birmingham adult cystic fibrosis clinic and the end of an epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Burkholderia cepacia in cystic fibrosis. Variable disease course.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Burkholderia cepacia complex: a contraindication to lung transplantation in cystic fibrosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Immunolocalisation of Burkholderia cepacia in the lungs of cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Intracellular survival of Burkholderia cepacia complex isolates in the presence of macrophage cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

In vitro activities of meropenem, PD 127391, PD 131628, ceftazidime, chloramphenicol, co-trimoxazole, and ciprofloxacin against Pseudomonas cepacia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Post-antibiotic effect of ceftazidime, ciprofloxacin, imipenem, piperacillin and tobramycin for Pseudomonas cepacia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

The effect of human lactoferrin on the MICs of doxycycline and rifampicin for Burkholderia cepacia and Pseudomonas aeruginosa strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Effect of antibiotic treatment on inflammatory markers and lung function in cystic fibrosis patients with Pseudomonas cepacia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Controlled study of Pseudomonas cepacia and Pseudomonas maltophilia in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Bacterial colonisation with Xanthomonas maltophilia--a retrospective study in a cystic fibrosis patient population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Microbiology of sputum from patients at cystic fibrosis centers in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Persistence and variability of Stenotrophomonas maltophilia in cystic fibrosis patients, Madrid, 1991-1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Use of random amplified polymorphic DNA PCR to examine epidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Endotoxic activity of lipopolysaccharides isolated from emergent potential cystic fibrosis pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Outbreak of Campylobacter food-poisoning in Northern Ireland

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Recommendations for susceptibility tests on fastidious organisms and those requiring special handling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Cathelicidin peptides inhibit multiply antibiotic-resistant pathogens from patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

“Celbenin” - resistant Staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Changing staphylococci and staphylococcal infections. A ten-year study of bacteria and cases of bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Staphylococcus aureus phage typing, antimicrobial susceptibility patterns and patient data correlated using a personal computer: advantages for monitoring the epidemiology of MRSA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Resistance to methicillin in isolates of Staphylococcus aureus from blood and cerebrospinal fluid in Wales, 1993-1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Methicillin-resistant Staphylococcus aureus: impact at a national cystic fibrosis centre

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Methicillin resistant Staphylococcus aureus (MRSA) infection in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Eradication of methicillin-resistant Staphylococcus aureus from a health center ward and associated nursing home

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

The influence of methicillin-resistant Staphylococcus aureus (MRSA) carriers in a nursery and transmission of MRSA to their households

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Nasal mupirocin treatment of pharynx-colonized methicillin resistant Staphylococcus aureus: preliminary study with 10 carrier infants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Topical mupirocin for eradication of MRSA colonization with mupirocin-resistant strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Comparative study of mupirocin and oral co-trimoxazole plus topical fusidic acid in eradication of nasal carriage of methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Recommendations for preventing the spread of vancomycin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

The independent evolution of resistance to ciprofloxacin, rifampicin, and fusidic acid in methicillin-resistant Staphylococcus aureus in Australian teaching hospitals (1990-1995). Australian Group for Antimicrobial Resistance (AGAR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Oral fusidic acid fails to eradicate methicillin-resistant Staphylococcus aureus colonization and results in emergence of fusidic acid-resistant strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Attempts to eradicate methicillin-resistant Staphylococcus aureus colonization with the use of trimethoprim-sulfamethoxazole, rifampin, and bacitracin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Eradication of colonization by methicillin-resistant Staphylococcus aureus by using oral minocycline-rifampin and topical mupirocin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Oxazolidinone antibiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Comparative activity of linezolid and other new agents against methicillin-resistant Staphylococcus aureus and teicoplanin-intermediate coagulase-negative staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Linezolid: pharmacokinetic characteristics and clinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Emendation of genus Achromobacter and Achromobacter xylosoxidans (Yabuuchi and Yano) and proposal of Achromobacter ruhlandii (Packer and Vishniac) comb. nov., Achromobacter piechaudii (Kiredjian et al.) comb. nov., and Achromobacter xylosoxidans sub

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Achromobacter xylosoxidans bacteremia: report of four cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Delayed onset and recurrent Alcaligenes xylosoxidans keratitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Alcaligenes infection in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Infection withBurkholderia cepaciaComplex Genomovars in Patients with Cystic Fibrosis: Virulent Transmissible Strains of Genomovar III Can ReplaceBurkholderia multivorans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Ventilator-associated pneumonia by Staphylococcus aureus. Comparison of methicillin-resistant and methicillin-sensitive episodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

Burkholderia cepacia complex genomovars and pulmonary transplantation outcomes in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256660

21 January 2018

Identifiers

DOI

10.1007/BF03256660

1 reference

9 August 2017

1 reference